€9.27
0.23%
L&S, Jun 28, 10:54 pm CET
ISIN
JP3942400007
Symbol
4503
Index
Sector
Industry

Astellas Pharma Share price

JPY1,590.00
+27.50 1.76% 1M
-94.50 5.61% 6M
-96.00 5.69% YTD
-602.50 27.48% 1Y
-420.50 20.92% 3Y
+55.00 3.58% 5Y
+259.00 19.46% 10Y
Tokyo, Closing price Fri, Jun 28 2024
ISIN
JP3942400007
Symbol
4503
Index
Sector
Industry

Key figures

Market capitalization JPY2.85t
Enterprise Value JPY3.52t
PER (TTM) P/E ratio 221.29
EV/FCF (TTM) EV/FCF 24.58
EV/Sales (TTM) EV/Sales 2.20
P/S ratio (TTM) P/S ratio 1.78
P/B ratio (TTM) P/B ratio 1.79
Dividend yield 4.65%
Last dividend (FY25) JPY74.00
Sales growth (TTM) Sales growth 5.60%
Turnover (TTM) Turnover JPY1.60t
EBIT (operating result TTM) EBIT JPY178.07b
Free cash flow (TTM) Free cash flow JPY143.27b
Cash position JPY335.69b
EPS (TTM) EPS JPY7.19
P/E ratio expected 42.82
P/S ratio expected 1.70
EV/Sales expected 2.10
Show more

Is Astellas Pharma a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

Astellas Pharma Share analysis

Unlock scores for free

Analyst opinions

14 Analysts have issued a Astellas Pharma forecast:

7x Buy
50%
6x Hold
43%
1x Sell
7%

Analyst opinions

14 Analysts have issued a Astellas Pharma forecast:

Buy
50%
Hold
43%
Sell
7%

Financial data from Astellas Pharma

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
1,603,671 1,603,671
6% 6%
100%
- Direct costs 391,304 391,304
20% 20%
24%
1,212,367 1,212,367
2% 2%
76%
- Selling and administrative expenses 582,270 582,270
11% 11%
36%
- Research and development costs 294,187 294,187
7% 7%
18%
335,910 335,910
14% 14%
21%
- Depreciation and amortization 157,840 157,840
49% 49%
10%
EBIT (operating result) EBIT 178,070 178,070
38% 38%
11%
Net profit 12,905 12,905
87% 87%
1%

Figures in millions JPY.

Don't miss a thing! We will send you all news about the Astellas Pharma share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Company profile

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Naoki Okamura
Employees 14,754
Founded 1923
Website www.astellas.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now